Storyline

FDA approves AstraZeneca’s new hypertension drug baxdrostat

AstraZeneca has received FDA approval for baxdrostat, a novel aldosterone synthase inhibitor developed in partnership with CinCor Pharma to treat hypertension.

Published 2026-05-18 10:26 UTCUpdated 2026-05-18 16:04 UTC
Current brief openSource links open
This current storyline is open here with summary, metadata, source links, continuity context, and full evidence. Paid is for compare-over-time, alerts, exports, and workflow.
No card needed for the free brief.
Evidence trail (top sources)
top sources (3 domains)domains are deduped. counts indicate coverage, not truth.
3 top sources shown
FDA approves AstraZeneca’s new kind of hypertension drug
BioPharma Dive · News · biopharmadive.com · 2026-05-18 16:04 UTC
AZ gets first okay for new hypertension drug baxdrostat
pharmaphorum · News · pharmaphorum.com · 2026-05-18 10:26 UTC
Overview

AstraZeneca has received FDA approval for baxdrostat, a novel aldosterone synthase inhibitor developed in partnership with CinCor Pharma to treat hypertension.

Score total
1.27
Momentum 24h
3
Posts
3
Origins
3
Source types
1
Duplicate ratio
0%
Why now
  • The FDA approval follows impressive phase 3 trial results reported last fall.
  • AstraZeneca aims to leverage this approval to boost revenue towards its $80 billion target by 2030.
  • Hypertension remains a major global health challenge, increasing demand for innovative therapies.
Why it matters
  • Baxdrostat offers a novel mechanism to treat hypertension, addressing an unmet medical need.
  • The drug’s approval could significantly impact AstraZeneca’s cardiovascular portfolio and revenue growth.
  • This milestone highlights successful collaboration between AstraZeneca and CinCor Pharma in drug development.
Continuity snapshot
  • Trend status: insufficient_history.
  • Continuity stage: emerging_confirmed.
  • Current status: open.
  • 3 current source-linked posts are attached to this storyline.
All evidence
Show filters & breakdown
Posts loaded: 0Publishers: 3Origin domains: 3Duplicates: -
Showing 3 / 0
Top publishers (this list)
  • BioPharma Dive (1)
  • Fierce Pharma (All) (1)
  • pharmaphorum (1)
Top origin domains (this list)
  • biopharmadive.com (1)
  • fiercepharma.com (1)
  • pharmaphorum.com (1)